Dr. Fishman’s area of interest is the measurement and therapeutic modulation of the capacity for anticancer immunotherapy. He focuses on the translational application of novel immune therapy to treatment of genitourinary cancer. Further translational clinical trials in kidney cancer therapy focused on dendritic cells and myeloid derived suppressor cell (MDSC) balance and function, during IL-2 immunotherapy. In a completed, phase 1 trial of a novel modified IL-2 drug, ALT-801, in which a T cell receptor epitope specific for the 264-272 peptide of p53 protein in the context of HLA-A2 was tested (M Fishman, 1R01FD003452-01.), the correlative immune pharmacodynamic testing was conducted at ALTOR, finding that the new drug induced the expected changes from IL-2 receptor maximal ligation. The drug went to phase 1b testing in melanoma, and a kidney cancer trial is in development.A pilot trial of intraprostatic injection of autologous dendritic cells during external beam therapy of localized, but high risk prostate cancer, demonstrated the feasibility of intratumor DC injection.Dr. Fishman’s future work is anticipated to address immune therapies in superficial bladder cancer, and application of DC phenotypic modulation in prostate cancer.